Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 ... - Morningstar
If approved, a vedolizumab biosimilar could increase access to an established IBD biologic by offering a lower-cost alternative, potentially reducing barriers to starting or continuing treatment for people with...